Definium Therapeutics, Inc. (DFTX)
Nasdaq: DFTX · Medicinal Chemicals & Botanical Products · New York, NY · filing with the SEC since 2020
Who owns Definium Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 8.3% of Common Stock, as its SCHEDULE 13G/A filed Feb 5, 2025 says.
Directors and officers
11
report now, of 18 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Feb 5, 2025 · Common Stock
Driehaus Capital Management LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 6.64% in Feb 17, 2026
Avoro Capital Advisors LLC
SCHEDULE 13G · filed Feb 17, 2026 · Common Shares, no par value per share
Deep Track Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Shares · reported falling below 5%, from 5.54% in Feb 13, 2026
Commodore Capital LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Shares, no par value per share · reported falling below 5%, from 7.2% in Feb 17, 2026
What DFTX reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
17sales
0purchases
17sales on a scheduled plan
5people selling
$7.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 18 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer | 5 | $4.0M | 5 | 0 | $0 |
| Sullivan Mark | Chief Legal Officer | 4 | $1.4M | 4 | 0 | $0 |
| Karlin Dan | Chief Medical Officer | 4 | $1.1M | 4 | 0 | $0 |
| Roberts Brandi | Chief Financial Officer | 2 | $300,000 | 2 | 0 | $0 |
| Wiley Matthew T. | Chief Commercial Officer | 2 | $200,000 | 2 | 0 | $0 |